- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Assessment
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Active Peptide Discovery Technology Service
- mRNA Immune Antibody Preparation Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
-
Technical Support
- Structural Basis for Selectivity and Antagonism in GPCR-Nanobodies
- Novel Peptide-Drug Conjugate (PDC) Shows Efficacy in Hepatocellular Carcinoma Models
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Customized Nano-antibody Immunogen3
- How much do you know about ADC drug development?
- Novel Cancer Therapeutic Strategy: Development of Bispecific Antibody-Drug Conjugates
- Nveiling the Molecular and Immunological Drivers of Antibody-Drug Conjugates (ADCs) in Cancer Treatment
- A PBD Dimer-Containing Antibody-Drug Conjugate (KK2845) Targeting TIM-3-Expressing AML
- A Novel Approach for Cancer Therapy - Modulating TCR Complex Recruitment to the T Cell Antigen Coupler (TAC) Enhances TAC-T Cell Function
- Development of Therapeutic Monoclonal Antibodies for Disease Treatment
- Common Problems and Solutions of Prokaryotic Expression of Recombinant Protein
- Neutralizing Monoclonal Antibody Development Service FAQ
- A Brief Discussion on Prokaryotic Expression of Recombinant Antibodies
- Common Problems and Solutions for Recombinant Antibody Yeast Expression Experiments
Special topic on antibody modification
- Eukaryotic System-Based Targeted Drug Discovery Platform: Yeast Display Technology
- Common Problems and Solutions for Yeast Two-hybrid Experiments
- Yeast Two-hybrid Technique Related Issues
- Common Problems and Solutions of Yeast Display Technology
- Overview of Yeast Two Hybrid System Principle and Application
- Introduction to Yeast Display Antibody Screening Technology
- Overview of Yeast Display Technology
- Overview of Yeast Two Hybrid Technology
- Yeast Display Platform for Rapid Nanobody Discovery
- What is the essential difference between antibody phage display and yeast display?
Yeast Display Technology Special Topic
- Yeast Two-Hybrid Technology Reveals a Novel Mechanism of Wheat Disease Resistance: How TaPIR1 "Hijacks" TaHRP1 to Suppress Chloroplast Function?
- Yeast Hybrid Library Construction: Smart Technology
- New Molecular Interaction Technology: How Much Do You Know About Yeast Hybridization Technology?
- Antibody Affinity Testing(SPR)
- Hybridoma Gene Sequencing Process
- Antibody Affinity Detection (BLI)
- Antibody Affinity Test EC50
- Antibody Full Length Sequencing
Antibody Detection Service Topic
- Novel Targeted Tumor Therapeutics: Efficacy of a Peptide-Drug Conjugate (PDC) in a Hepatocellular Carcinoma Model
- Non-Invasive In Vivo Monitoring of PROTAC-Mediated Protein Degradation Using an Environment-Sensitive Reporter
- How do you know Phage Display Peptide Library?
- Phage Display Peptide Library
- Phage Display Antibody Library Technology
- Efficient Screening Methods and Research Progress of Anti-tumor Polypeptides
- Molecular Screening and Application of Targeted Peptides
- Screening Strategies for Cyclic Peptide Drugs
- Construction Method of Random Peptide Library
- Construction and Screening of Peptide Library
Special Topic on Phage Display Technology
- A Promising Novel Cancer Therapeutic Strategy: Aptamer-Drug Conjugates (ApDCs)
- A Novel Therapeutic Approach for Multiple Myeloma: Development of a CD38 and CD47 Bispecific Bipartopic Antibody
- A Novel Therapeutic Approach - CAR-M
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Discovery Service
CAR-T Molecule Discovery Topic
- The Promise of Small Nucleic Acid Therapeutics: From Bench to Clinic as Next-Generation Medicines
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Overview of Aptamer Synthesis Technology
- Screening and optimization of nucleic acid aptamers
- Screening and Application of Peptide Aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Research Progress of Aptamer Screening-of Small Molecule Targets
- Nucleic Acid Aptamer Libraries Screening: an Efficient Method for Discovering Specific Binding Molecules
Molecular Biology Service Topics
-
Product Center
- Contact Us
With its leading technology platform and rich experience, Tek Biotech provides global customers with complete solutions from the discovery, design to production and application of nanoantibodies.
TekBiotech has been committed to protein expression and sequencing research for many years. Based on high-resolution mass spectrometry and high-fidelity gene cloning technology, we are able to provide customers with high-fidelity antibody and protein sequencing services.
Tek Biotech provides comprehensive yeast one-hybrid services, focusing on studying DNA-protein interactions. Our services include transcription factor identification, target gene cloning, and gene regulation studies. Choose Tek Biotech and enjoy customized, highly sensitive yeast one-hybrid solutions.
After years of technological accumulation, Tek Biotech has built a complete phage display technology system and yeast display system to provide customers with high-quality Car lead antibody molecule discovery services.
Tek Biotech has mature antibody humanization technology and is committed to building a complete one-stop technical service platform. It can provide a series of services from bioinformatics analysis, humanized antibody design, antibody expression and purification, to affinity determination, antibody affinity maturation, etc. to meet the needs of different customers.
Tek Biotech is committed to providing excellent nano-antibody services, especially in the preparation of different immunogens. We use advanced technologies to efficiently prepare nano-antibodies against a variety of immunogens, including proteins, peptides, viruses, cells and small molecules.
Based on the phage display technology platform, TekBiotech can provide major experimental links including antigen design, alpaca immunization, library construction and screening (solid/liquid screening), and active function verification, and screen highly specific and high-affinity camelid VHH antibodies for scientists around the world.
Tek Biotech is a professional CRO service provider that can provide customers with high-quality antibody epitope mapping services, as well as antibody discovery and production services, such as antibody construction and expression services for scfv antibody fragments, fab antibody fragments, sdAb single domain antibodies, etc.
TekBiotech's antibody drug candidate molecule discovery platform based on phage display technology can provide services such as VHH nanobody, scFv antibody, Fab antibody, CAR-T lead antibody sequence design, CAR-NK lead antibody sequence design, etc.
TekBiotech has a stable mammalian CHO cell and prokaryotic cell nanoantibody expression platform, and can provide customers with one-stop services from antibody sequence analysis, linker design, label selection design, vector selection design to exploration and optimization of recombinant nanoantibody expression conditions, recombinant antibody purification, etc.
